Get the Stockscreener App
0.93
2.40%
-0.0229
After Hours:
.92
-0.01
-1.08%
Celularity Inc stock is traded at $0.93, with a volume of 28,703.
It is down -2.40% in the last 24 hours and down -33.57% over the past month.
Celularity Inc is a clinical-stage biotechnology company developing off-the-shelf placental-derived allogeneic cell therapies including genetically modified and unmodified NK cells, engineered T cells including CAR-T cells, and mesenchymal-like adherent stromal cells, targeting indications across cancer, immunologic, infectious, and degenerative diseases. It manages its operations through an evaluation of three distinct business segments which include Cell Therapy, Degenerative Disease, and bio-banking. The company generates the majority of its revenue from the bio-banking segment.
See More
Previous Close:
$0.9529
Open:
$0.96
24h Volume:
28,703
Relative Volume:
0.17
Market Cap:
$26.92M
Revenue:
$40.58M
Net Income/Loss:
$-80.65M
P/E Ratio:
-0.2792
EPS:
-3.331
Net Cash Flow:
$-8.11M
1W Performance:
-3.12%
1M Performance:
-33.57%
6M Performance:
-44.97%
1Y Performance:
-44.97%
1-Day Range:
$0.92
$0.9799
1-Week Range:
$0.88
$1.149
52-Week Range:
$0.88
$4.35
Celularity Inc Stock (CELU) Company Profile
Name
Celularity Inc
Sector
Industry
Phone
(908) 768-2170
Address
170 PARK AVE, FLORHAM PARK
Compare CELU vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CELU
Celularity Inc
|
0.93 | 27.58M | 40.58M | -80.65M | -8.11M | -3.331 |
VRTX
Vertex Pharmaceuticals Inc
|
427.65 | 107.87B | 12.32B | 4.34B | 3.19B | 16.86 |
REGN
Regeneron Pharmaceuticals Inc
|
721.05 | 73.63B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
807.55 | 49.42B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
303.00 | 40.20B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
313.32 | 33.06B | 5.36B | 287.73M | 924.18M | 2.5229 |
Celularity Inc Stock (CELU) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-30-23 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| Dec-22-22 | Downgrade | Oppenheimer | Outperform → Perform |
| Jun-22-22 | Initiated | H.C. Wainwright | Buy |
| Apr-06-22 | Downgrade | Truist | Buy → Hold |
| Jan-28-22 | Initiated | Oppenheimer | Outperform |
| Nov-24-21 | Initiated | Morgan Stanley | Equal-Weight |
View All
Celularity Inc Stock (CELU) Latest News
NEXGEL Appoints Brian Kieser and Kevin Harris from New - GlobeNewswire
NEXGEL Appoints Ian Blackman CFO Amid Celularity Deal - MyChesCo
Celularity Announces Filing of Form 10-K, Regains Nasdaq Compliance and Highlights Continued Strategic Transformation - Investing News Network
Stocks to watch on Friday after hours: CTLP, CELU, ULH (CTLP:NASDAQ) - Seeking Alpha
Celularity regains Nasdaq compliance after filing annual report By Investing.com - Investing.com South Africa
Celularity regains Nasdaq compliance after filing annual report - Investing.com
Nasdaq closes Celularity listing case after delayed 10-K filing - Stock Titan
Celularity Inc. 2025 Annual 10-K Report: Financials, Debt, Equity, and Major Agreements Overview - Minichart
Celularity : Annual Report for Fiscal Year Ending December 31, 2025 (Form 10-K) - marketscreener.com
[10-K] Celularity Inc Files Annual Report - Stock Titan
NEXGEL (NASDAQ: NXGL) hires new CFO to support Celularity deal - Stock Titan
Celularity Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - marketscreener.com
NEXGEL Closes Celularity Asset Deal, Launches BioNX Surgical - MyChesCo
NEXGEL expects pro forma annual revenue of roughly $35M following Celularity wound segment acquisition - MSN
Celularity (CELU) Registration Filing Summary - Quartr
NEXGEL Appoints Ian Blackman as Chief Financial Officer - Investing News Network
Nexgel, Inc. Appoints Ian Blackman as Chief Financial Officer - marketscreener.com
NEXGEL taps M&A veteran as CFO to steer Celularity integration - Stock Titan
Inside the deal: After investor bails, Nexgel scrambles to save acquisition that will triple revenue - The Business Journals
Celularity receives Nasdaq notification - MSN
Celularity Inc (CELU) insider Form 3 details warrants and convertible notes - Stock Titan
Celularity Inc (CELU) insider lists warrant and note holdings - Stock Titan
Barach Family Trust (CELU) reports warrants and convertible notes in Celularity Form 3 - Stock Titan
CELU Celularity tops Q3 2025 EPS estimates and posts sharp revenue growth, as shares dip 2.08%.Guidance Upgrade - Cổng thông tin điện tử tỉnh Lào Cai
Celularity (CELU) What Lies Ahead | Celularity Inc posts 42.5% EPS beat, narrower lossDistressed Pick - Cổng thông tin điện tử tỉnh Lào Cai
Celularity (CELUW) Stock: Is It Breaking Uptrend Earnings ReportNCAV - Xã Thanh Hà
CELU (Celularity Inc.) Q3 2025 EPS beats analyst expectations, registers a small post-earnings stock dip.Secondary Offering - Xã Thanh Hà
Family trust reports 20.1% Celularity (CELU) stake from $10M financing - Stock Titan
NEXGEL Reschedules Shareholder Call, Revises Celularity Financing - MyChesCo
NEXGEL closes Celularity biomaterials deal, raises $5.5 million By Investing.com - Investing.com India
Celularity Announces Closing of Transaction with NexGel - Investing News Network
Nexgel Inc co and Celularity enter amendment no. 1 to license agreement on April 17, 2026 - marketscreener.com
Nexgel IncCo to Pay Celularity $13.3 Mln I - Moomoo
NexGel Closes Celularity Biomaterials License Terms and Secures $6.9M Convertible Note Financing - TradingView
NEXGEL (NASDAQ: NXGL) triples revenue outlook with Celularity deal, $6.9M notes - Stock Titan
Celularity Inc. announced that it has received $13.3 million in funding from NEXGEL, Inc. - marketscreener.com
NexGel closes acquisition of products from Celularity - TipRanks
Celularity Closes $13.3 Million Asset Sale to NexGel, Strengthening Focus on Longevity Therapeutics and Balance Sheet 1 - Minichart
NEXGEL New Strategic Partner, Sequence LifeScience, Leads Financing with $5.5 Million to Complete Acquisition of Celularity Degenerative Disease Segment - Investing News Network
Nexgel new strategic partner, Sequence LifeScience, leads financing with $5.5 million to complete acquisition of Celularity degenerative disease segment - marketscreener.com
Celularity Closes NexGel Asset Sale, Refocuses on Cell Therapy - TipRanks
NEXGEL closes Celularity biomaterials deal, raises $5.5 million - Investing.com
Biomaterials company Nexgel announces a key partnership with new strategic partner Sequence Lifescience™ - Bitget
NEXGEL New Strategic Partner, Sequence LifeScience™, Leads Financing with $5.5 Million to Complete Acquisition of Celularity Degenerative Disease Segment - The Manila Times
Celularity Inc. Announces Management Resignations - marketscreener.com
Celularity (NASDAQ: CELU) closes NexGel asset sale as Helena note default looms - Stock Titan
NEXGEL New Strategic Partner, Sequence LifeScience™, Leads - GlobeNewswire
Celularity Closes Transaction with NexGel to Monetize Biomaterials - Intellectia AI
NEXGEL, Inc. completed the acquisition of Portfolio of Commercial-stage Regenerative Biomaterial Products of Celularity Inc. for 15.8 million. - marketscreener.com
Celularity Announces Receipt of Nasdaq Notice Regarding Late Form 10-K Filing - The Manila Times
Celularity receives Nasdaq notice for delayed annual report filing By Investing.com - Investing.com Australia
Celularity Inc Stock (CELU) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.77%
0.25%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):